We are thrilled to announce the first TEACH Course in the Center of Excellence for PulseCath iVAC 2L, pVAD – Percutaneous Ventricular Assist Device, in Italy hosted by…

🌟 The CEO Views is proud to recognize PulseCath, a medical device company as one of the ‘Top 50 Most Innovative Companies to Watch 2024’. The award felicitates…

🚀 We are thrilled to announce the first protected High-Risk PCI with the successful support of iVAC 2L performed by Drs. Hatim Al-Lawati and Dr. Khalid Al-Saidi Royal…

We proudly announce the successful achievement of the transition from Medical Device Directive (MDD) CE marking to Medical Device Regulation (EU) 2017/745 (MDR) for our groundbreaking product, iVAC…

We are thrilled to announce a significant milestone in our mission to advance healthcare and improve patient outcomes. Prof.dr. Paul Knaapen and Dr. Alex Nap (Principal Investigator) enrolled…

🔎 Exciting News from the Romanian CTO Workshop in Oradea, Romania. We are thrilled to share that a live case demonstration was taking place at this event, showcasing…

📢 PulseCath expands in China and Asia-Pacific (APAC) region. We are delighted to share the news of the first successful iVAC 2L case in China. The procedure was performed…

🚀A new milestone in New Zealand 🚀 We are thrilled to announce the first protected High-Risk PCI with the successful support of iVAC 2L performed by Dr. Sanjeevan…

🚀A new milestone in Jordan 🚀 We are thrilled to announce the first protected High-Risk PCI with the successful support of iVAC 2L performed by Dr. Amer Al…

🌍 Exciting news! Another important milestone for expanding the market in the Middle East. We are thrilled to announce the achievement of product registration for iVAC 2L in…